# 1 Title - Investigating immune amnesia after measles virus

# 2 infection in two West African countries: A study protocol

3 Short Title - Investigating immune amnesia in two West

# 4 African countries

5

#### 6 Authors

- 7 Karine Fouth Tchos<sup>1</sup>, Renée Ridzon<sup>1</sup>, Mory Cherif Haidara<sup>2</sup>, Djeneba Dabitao<sup>3</sup>, Esther Akpa<sup>1</sup>, Daouda
- 8 Camara<sup>2</sup>, David Vallée<sup>4</sup>, Mariam Coulibaly<sup>3</sup>, Sekou Camara<sup>2</sup>, Jamila Aboulhab<sup>1</sup>, Mahamadou Diakité<sup>3</sup>,

9 Bassirou Diarra<sup>3</sup>, Samba Diarra<sup>3</sup>, Ilo Dicko<sup>3</sup>, Alyson Francis<sup>5</sup>, Cécé Francis Kolié<sup>2</sup>, Michel Koropogui<sup>2</sup>, Caeul

- 10 Lim<sup>4</sup>, Seydou Samaké<sup>3</sup>, Sally Hunsberger<sup>1</sup>, Moussa Sidibé<sup>2</sup>, Ray Y. Chen<sup>1</sup>, Issa Konate<sup>3</sup>, Seydou Doumbia<sup>3</sup>,
- 11 Abdoul Habib Beavogui<sup>2</sup>, and Kathryn Shaw-Saliba<sup>1</sup>

12

<sup>1</sup>Division of Clinical Research, NIAID/NIH, Rockville, Maryland, USA

<sup>2</sup>Centre National de Formation et de Recherche en Santé Rurale (CNFRSR) de Maferinyah, Conkary,

Guinea

<sup>3</sup>University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako,

Bamako, Mali

<sup>4</sup>Clinical Monitoring Research Program Directorate (CMRPD), Frederick National Laboratory for Cancer

Research, Frederick, Maryland, USA

<sup>5</sup>Systex, Inc, Rockville, Maryland, USA

#### 13 Data availability

14 This article does not report any data and the data availability policy is not applicable.

# 15 Abstract

16 "Investigation of Immune Amnesia Following Measles Infection in Select African Regions" 17 (ClinicalTrials.gov Identifier: NCT06153979) is a prospective, observational, longitudinal study being 18 conducted in two West African countries, Guinea, and Mali. The overall goal is to investigate the impact 19 of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to 20 subsequent illness. A total of 256 children aged 1 to 15 years are being enrolled into one of two study 21 arms: those with acute MeV infection (cases) and without (controls). Acute MeV is confirmed by RT-PCR 22 testing on upper respiratory specimens or IgM detection on blood samples at screening. Blood samples 23 are collected at multiple time points at screening (Day 0), at an optional visit to repeat IgM serology for 24 inconclusive or negative Day 0 results (Day 7-10), and during follow-up visits on Day 14, Week 13, and 25 Week 52. These blood samples will be tested to evaluate both humoral and cellular immune responses to 26 endemic pathogens to measure variations in antibody diversity and antibody secreting cells (ASCs). To 27 explore how recent MeV infection may affect the child's ability to respond to a controlled immune 28 stimulus, all participants will receive rabies vaccine pre-exposure prophylaxis (PrEP) using Verorab 29 inactivated rabies vaccine. Three doses of 0.5 ml of VERORAB vaccine are administered on Days 0, 7, and 30 28. Biological samples will be collected after vaccination to assess if the rabies vaccine response differs: 31 1) between cases and controls, and 2) based on the timing of the rabies vaccination after acute measles 32 infection. In addition, the study team will collect information on healthcare encounters during the year-33 long follow-up will be collected to determine if there is a difference in the number of encounters by study 34 group. The findings of this study will further the understanding of the MeV immune amnesia phenotype. 35

# 36 Introduction

37 Measles virus (MeV) infection is a major cause of death globally for children under five years of age [1-3]. 38 There are reports of increases in cases in many countries, including in West Africa [4, 5]. The Expanded 39 Program on Immunization in Guinea and Mali calls for two doses of measles vaccine starting at 9 months 40 [6, 7]. According to WHO/UNICEF national immunization coverage estimates for the African region in 41 2022, 69% of children received the first measles vaccine and 45% received the second [6]. The rates in 42 Mali were very close to these averages, at 70% for the first dose and 44% for the second dose, but Guinea 43 lagged farther behind, at 47% and 3%, respectively [8]. These rates are far below the 92-95% level 44 required for herd immunity and control of community transmission of measles [9]. This is largely due to 45 the fact that, over the past decade, West Africa has experienced measles outbreaks following large-scale 46 public health emergencies, such as the Ebola epidemic and the COVID-19 pandemic, which have disrupted 47 global routine childhood vaccine coverage [10-12]. Armed conflict has also disrupted routine vaccinations 48 in many countries, resulting in a disproportionate number of cases of vaccine preventable diseases, 49 including measles [13, 14]. Finally, some vaccination campaigns may have used vaccines where 50 appropriate storage conditions were not maintained due to a lack of available resources or equipment. 51 Thus, the presence of global measles outbreaks underscores the importance of studies that will contribute 52 to a better understanding of the effect of MeV infection on morbidity and mortality. 53 MeV infection not only directly causes morbidity but is also associated with increased susceptibility to

other infections and/or increased hospitalizations [<u>15-19</u>]. Measles vaccination has been associated with larger reductions in morbidity and mortality than would be expected if caused by acute MeV infection alone [<u>19-24</u>]. While there is a strong immune response to MeV infection that confers life-long immunity to MeV there is some evidence of a loss of existing immunity to other pathogens. This

58	phenomenon, known as "immune amnesia" [ $25$ ], is associated with a loss of memory B cells and
59	reduced antibody repertoires from previous infections and vaccinations [ $26$ , $27$ ]. MeV-induced immune
60	amnesia has been characterized in animal studies with ferrets and rhesus macaques and has also been
61	examined in European populations [ $26$ , $28$ , $29$ ]. Given the current outbreaks of measles in West Africa,
62	this study aims to determine whether measles-induced immune amnesia occurs in African regions and
63	affects immune responses to endemic pathogens such as Mycobacteria tuberculosis, Plasmodium
64	species, and arthropod-borne viruses (e.g., yellow fever virus or dengue). The hypothesis of this study is
65	that acute MeV infection induces a loss of pre-existing immunity to pathogens prevalent in select African
66	regions. Compared to those who do not have acute MeV infection, acute MeV infection will result in 1) A
67	loss of antibody diversity from previous infections and/or vaccinations compared to baseline; 2) Altered
68	immune response to a controlled immune stimulus (rabies vaccination) given at two different
69	timepoints; 3) Increased incidence of illnesses or healthcare encounters in the year following acute MeV
70	infection.
71	

The data gathered in this study will better characterize the effect and mechanism of measles-induced

73 immune amnesia in children. The design of this study is described.

# 74 Material and methods

## 75 Ethical statement

76 National Institute of Allergy and Infectious Diseases (NIAID) is the sponsor of the study. The main

77 protocol and each of the site-specific appendices received approval from local ethics committees and/or

78 health authorities prior to study implementation including the University of Sciences, Techniques and

79 Technologies Bamako Mali #2023/210/CE/USTTB -Sept 18, 2023, and Guinea CNERS # 145/CNERS/23 -

80 Sept 8, 2023. Prior to initiation of any study procedures, all study participants must have an informed

81 consent signed by a parent or guardian, and an assent as applicable, in a language they understand.

### 82 Clinical study design

- 83 Study Overview: "Immune Amnesia Following Measles Infection in Select African Regions"
- 84 (ClinicalTrials.gov Identifier: NCT06153979), is a prospective, observational, longitudinal study being
- 85 conducted in West Africa to investigate the effects of MeV infection on pre-existing immunity, vaccine
- 86 response, and susceptibility to subsequent illnesses. A total of 256 children are being enrolled into 1 of 2
- 87 arms: acute MeV infection (cases) or no acute MeV infection (controls) as assessed using RT-PCR on
- 88 upper respiratory specimens and IgM on blood samples. Blood samples are collected at Screening (Day
- 89 0), optional repeat IgM serology for inconclusive or negative Day 0 results (Day 7-10), and at follow-up
- 90 visits (Day 14, Week 13, and Week 52). The blood samples will be tested for humoral and cellular
- 91 immune responses to endemic pathogens to determine changes in antibody diversity and antibody
- 92 secreting cells (ASCs).
- 93

94 To explore how recent MeV infection affects the ability to respond to an immune stimulus, participants 95 will receive rabies vaccine pre-exposure prophylaxis (PrEP) with Verorab inactivated rabies vaccine 96 (Sanofi) as part of the study. Rabies vaccine is an immunogen to which most participants have not been 97 exposed and thus can be used to measure the immune response to a newly encountered antigenic 98 stimulus. Additionally, as rabies is estimated to cause 59,000 human deaths annually worldwide with the 99 highest mortality in Africa [30, 31], the provision of rabies PrEP is a benefit to participants in the study 100 [32]. All children in each arm will receive rabies vaccination (3-dose series at Days 1, 7 and 28 given as 101 PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment. WHO now 102 recommends a 2-dose PrEP schedule [31]. However, we decided to use the older 3-dose schedule from

103	the Verorab package insert ( <u>https://www.medicines.org.uk/emc/files/pil.15572.pdf</u> ) to give the acute
104	measles cohort children the best chance of developing an immune response in the event of persisting
105	immune amnesia. Biological samples will be collected after vaccination to assess if the immune stimulus
106	(rabies vaccine) response differs: 1) between children with and without MeV infection, and 2) based on
107	the timing of the receipt of the rabies vaccine. A participant who is potentially exposed to rabies during
108	study participation will be provided rabies post exposure prophylaxis (PEP) with Verorab vaccine, with or
109	without human rabies immune globulin, based on published recommendations [32]. The study schedule
110	is depicted in Figure 1.
111	Fig 1: Study Schedule
112	Abbreviations: AE, adverse event; HIV, human immunodeficiency virus; Ig, immunoglobulin; MUAC, mid-
113	upper arm circumference; NP, nasopharyngeal; OP, oropharyngeal; PCR, polymerase chain reaction.
114	(X) = Each participant will receive only one 3-dose series of rabies vaccine according to randomization to
115	early group (vaccination at Visits 2, 3, and 4) or late group (vaccination at Visits 8, 9, and 10).
116	<sup>a</sup> EARLY rabies vaccination: Only participants randomized to EARLY rabies vaccine attend Visits 2, 3, 4.
117	Visit 2 occurs 8 weeks after Day 0; Visit 3 occurs 7 days after Visit 2; Visit 4 occurs 21 to 28 days after
118	Visit 2 AND at least 14 days after Visit 3.
119	<sup>b</sup> LATE rabies vaccination: Only participants randomized to LATE rabies vaccine attend Visits 8, 9, 10. Visit
120	8 occurs 47 weeks after Day 0; Visit 9 occurs 7 days after Visit 8; Visit 10 occurs 21 to 28 days after Visit
121	8 AND at least 14 days after Visit 9.
122	<sup>c</sup> Day 0 is defined as the day screening occurs and the first research blood sample is collected.
123	Inclusion/exclusion criteria evaluation for enrollment will be completed when PCR and measles
124	IgG/IgM and HIV results are available, generally by Day 14. All potential participants (or
125	guardian/parent) will be informed of eligibility status by a designated study staff by phone, if possible,
126	prior to the Day 14 scheduled study visit or at the Day 14 scheduled study visit. Ineligible participants

- 127 may be invited to the site to discuss test results and referral for measles vaccination if serum IgG and
- 128 IgM are both negative.
- <sup>d</sup> Vital signs include temperature, heart rate, and respiratory rate; may be obtained prior to rabies
- 130 vaccine administration, if clinically indicated.
- <sup>e</sup> MUAC in children 12 to 59 months old.
- <sup>1</sup>32 <sup>f</sup> HIV testing for children younger than 24 months will be performed via PCR and repeated with Rapid
- 133 Diagnostic Test (RDT) at end of study to adhere to national guidelines; HIV RDT will be performed at
- 134 screening for participants 24 months and older and will not be repeated at end of study.
- <sup>g</sup> HIV and measles serum IgM/IgG results must be reviewed for eligibility confirmation prior to Day 14.
- <sup>136</sup> <sup>h</sup> Blood will be collected for hemoglobin test via finger and/or heel stick. Hemoglobin and urine
- 137 pregnancy rapid test results must be reviewed prior to venous blood sample collection.
- <sup>1</sup>38 <sup>i</sup> Females of child-bearing potential must have a negative pregnancy test prior to enrollment and each
- 139 rabies vaccine administration.
- <sup>140</sup> <sup>j</sup>Measles vaccination to be administered to control participants (through the study or referral to
- 141 Ministry of Health vaccination program) if serum measles IgG and IgM are both negative.
- <sup>k</sup>5 mL is the maximum volume that will be obtained at each blood draw.
- <sup>1</sup>Vitamin A will be administered at D0 to all participants with clinical measles per WHO guidelines: 2 oral
- 144 doses of 200,000 IU given 24 hours apart. The first dose will be administered at the study site and the
- second will be provided to the parent to be administered 24 hours later.
- 146
- 147 The study team will collect, to the extent possible, information on healthcare encounters for evaluation
- 148 and treatment of illness during the year-long follow-up to determine if there is a difference in the
- 149 number of encounters by study group.
  - 8

150 The study objectives and endpoints are shown in Table 1.

#### 151 Table 1: Study objectives and endpoints

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
Primary		
To determine if MeV infection	Mean change in a panel of antibody	These methods detect
induces a loss of pre-existing	levels over 13 weeks as measured by	antibodies against multiple
immunity (immune amnesia) to	multiplex serological methods (e.g.,	diverse pathogens and epitopes
endemic pathogens at Week 13	Molecular Indexing of Proteins by Self-	and assess both neutralizing
after baseline in children in select	Assembly (MIPSA) with an updated	and non-neutralizing
African regions.	VirScan library and additional libraries	antibodies.
	with endemic bacteria and parasite)	
	and targeted ELISAs for confirmation.	
To determine the effect of MeV	Geometric mean RVNA titer 5-6 weeks	These tests will measure the
infection on immune response to a	after the first rabies vaccine dose.	immune response and
controlled immune stimulus (rabies	Proportion of subjects with an RVNA	functionality of antibodies
vaccination) at early and late	titer $\geq$ lower limit of quantification 5-6	raised against the rabies
timepoints post-infection.	weeks after the first rabies vaccine	vaccine.
	dose.	
	Proportion of subjects with rabies	
	virus neutralizing antibodies (RVNA)	

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
	titer ≥ 0.5 International Units per	
	milliliter (IU/mL) as measured by rapid	
	fluorescent focus inhibition test 14	
	days after the last PrEP regimen	
	vaccination.	
Secondary		
To determine if there is an increase	Mean number of non-study sick visit	Visits to the healthcare system
in healthcare system encounters in	healthcare system encounters during	for sick visits in the year
the year following enrollment in	the 1-year follow-up.	following enrollment in children
children with recent MeV infection		with recent MeV infection will
compared to those without recent		help determine the clinical
MeV infection.		impact of the immune amnesia
		in an objective manner.
To determine if MeV infection	Mean change in a panel of antibody	These methods detect
induces a loss of pre-existing	levels over 52 weeks as measured by	antibodies against multiple
immunity (immune amnesia) to	multiplex serological methods (e.g.,	diverse pathogens and
endemic pathogens at Week 52	MIPSA with an updated VirScan library	epitopes. These represent the
after baseline in children in select	and additional libraries with endemic	spectrum of both neutralizing
African regions.	bacteria and parasite) and targeted	and non-neutralizing
	ELISAs for confirmation.	antibodies.

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
Exploratory		
To assess the appearance and	Mean change in cell number and	Assessing the number and
continued production of B and T	functionality from baseline to 14 days.	functionality of the B and T cells
cells, especially ASCs from		including ASCs will give insight
peripheral blood mononuclear cells		into the impact of MeV on B
(PBMCs) in circulation following		cell development and humoral
MeV infection in children 1-15 years		immunity.
old in a subset of participants,		
depending on availability of		
collected blood samples.		
To attempt to identify the etiology	Unbiased next generation sequencing	This may identify other
of illness in children who present	for pathogen discovery directly from	pathogens that may mimic the
with signs and symptoms consistent	the oropharyngeal	clinical presentation of MeV in
with measles and are screened but	(OP)/nasopharyngeal (NP) swab.	children who have symptoms
not enrolled due to negative		but test negative.
measles PCR and IgM.		
To identify the genotypes of MeV	Next generation sequencing or	This will allow identification of
collected in the study.	targeted Sanger sequencing directly	different genotypes of MeV in
	from the OP/NP.	the countries enrolling
		participants.

OBJECTIVES	ENDPOINTS	JUSTIFICATION FOR ENDPOINTS
To characterize the phenotype of	Differences in rash	This will allow for a comparison
the rash and/or Koplik spots in	patterns/presentation in children who	of rash and/or Koplik spot
children who present with signs and	test positive versus those who test	presentation in potential cases
symptoms consistent with measles	negative for measles based on	that end up testing positive or
who test positive for measles	analysis of photographs.	negative for measles in the
(polymerase chain reaction [PCR]		laboratory. This will
and/or IgM positive) and who test		complement the exploratory
negative for measles (PCR and IgM		objective of identifying the
negative).		etiology via unbiased next
		general sequencing in the
		participants who test negative
		for measles. In addition, we can
		contribute images of measles
		rash on dark skinned children
		and Koplik spots to the medical
		literature.

### 152 Eligibility

- 153 The study inclusion and exclusion criteria are shown in Table 2. Children aged 1-15 years who are eligible
- after initial screening are enrolled in Group 1 of children with acute MeV infection (cases) or Group 2 of
- 155 children OP eligible for the study and will be referred for care. An upper respiratory specimen (O

- 156 oropharyngeal (OP)/nasopharyngeal (NP)) for MeV PCR and plasma for measles IgM/IgG serology are
- 157 collected. Plasma and PBMCs are also collected at screening for research assays. PBMCs will only be
- 158 collected in Mali due to operational constraints and lack of dry ice in Guinea. Anyone suspected of
- 159 having measles at the time of screening will be treated with Vitamin A 200,000 IU by mouth per day for
- 160 2 days, as recommended by the World Health Organization [33].

#### 161 Table 2: Study Inclusion and Exclusion Criteria

Inclusion Criteria		Exclusion Criteria
1.	Aged 1 to 15 years.	1. HIV infection or any other
2.	Ability of the participant's legal or	immunosuppressive condition or
	culturally acceptable representative to	medications.
	provide informed consent.	2. Pregnant or lactating.
3.	Ability to give assent, as appropriate.	3. History of prior measles or immunologic
4.	Stated willingness of parent/guardian	evidence of prior measles in the absence
	and participant as appropriate, to	of prior measles vaccination.
	comply with all study procedures.	4. Severe anemia, defined as hemoglobin
5.	Willingness to receive rabies vaccine.	less than 8 g/dL.
6.	Meet the criteria for assignment to	5. Any acute or chronic condition which, in
	Group 1 or Group 2, as follows:	the opinion of the investigator,
	a. Group 1, cases (acute MeV	constitutes a contraindication to
	infection):	participation in this study.
	Clinical signs and symptoms	
	suggestive of acute MeV	

infection (Koplik spots or skin

rash) AND

• Laboratory confirmed measles:

• Upper respiratory specimen

(swab) PCR for measles

positive.

OR

○ Serum IgM for measles

positive.

b. Group 2, controls (no acute MeV

infection):

 No clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND

- Upper respiratory specimen
   (swab) PCR negative for MeV
   AND
- Serum measles IgM negative
   AND
- Serum measles IgG positive and previously vaccinated for measles (2<sup>nd</sup> dose will be

offered if appropriate). If	
serum measles IgG is negative,	
participant must be willing to	
be vaccinated regardless of	
prior measles vaccine history	
to meet this criterion.	

162

#### 163 Study visits according to initial protocol

164 A schematic depiction of the study visit timing is shown in fig 1. During Visit 0 on Day 0, demographic, 165 medical history, vaccination history and concomitant medication information are collected, and a 166 physical exam is performed. Mid upper arm circumference is obtained in children ≤59 months. Due to 167 the turnaround time for the MeV PCR and measles IgM/IgG in the laboratory, eligibility as a case or 168 control is confirmed at Visit 1 on Day 14. Measles vaccination will be administered to controls who do 169 not have a positive measles IgG at this visit. Once enrolled, participants will be randomized to receive 3 170 doses of rabies vaccine as PrEP early (doses at Weeks 8, 9, 11-12) or late (doses at Weeks 47, 48, 50-51). 171 At Weeks 26 and 39, a healthcare questionnaire will be administered. Windows around study visits are 172 relatively short so that the targeted endpoints can be captured accurately. Visits that occur out of the 173 window periods are permitted under special circumstances, to avoid missed visits. A research blood 174 sample is collected at Days 0 and 14, and Weeks 13 and 52; prior to collection of blood, hemoglobin is 175 checked in all participants via a fingerstick, and a urine pregnancy test is obtained in females starting at 176 their reproductive age. Anyone found to be pregnant is withdrawn from the study. If the hemoglobin is

- 177 <8 g/dl at the follow up blood draw visits, the participant remains in the study, but a blood sample is not
- 178 collected.
- 179 Fig 2: Study Schematic
- 180 <sup>1</sup>Research blood samples
- 181 <sup>2</sup> Measles vaccination in controls if confirmed to have negative serum measles IgG
- 182 <sup>3</sup> Rabies vaccine Dose 2 is given 7 days +2 days after Dose 1, and Dose 3 is given at Day 21 to Day 28
- 183 after Dose 1 and at least 14 days after Dose 2
- 184 <sup>4</sup>Healthcare utilization assessment

#### 185 Study sites

- 186 This study is being conducted in Guinea and Mali, which were chosen based on measles epidemiology,
- 187 existing research infrastructure, and ongoing partnerships between their Ministries of Health, and in
- 188 Mali, the Ministry of Higher Education, and the National Institute of Allergy and Infectious Diseases
- 189 (NIAID) in the United States.
- 190 The Partnership for Clinical Research in Guinea (PREGUI) aims to conduct and implement a program of
- 191 national and international, high-quality research on public health priorities in Guinea, and to build and
- develop sustainable research capacity. This study is implemented at two sites under PREGUI, both
- 193 located within treatment centers for diseases with epidemic potential at referral hospitals in Forécariah
- 194 and Mafèrinyah. These sites receive referrals from surrounding health centers, health posts and
- 195 communities and are each served by a multidisciplinary team.
- 196 The University Clinical Research Center (UCRC) is located at the University of Sciences, Techniques, and
- 197 Technologies of Bamako in Mali. Its mission is to promote clinical research and training at international
- 198 standards in Mali and within the West Africa region. The UCRC offers competence in clinical research

199	including clinical operations, laboratory diagnosis and exploration of immune function, data
200	management, pharmacy and community engagement. The research team recruits participants from the
201	Commune VI Reference Health Center and the Bakorobabougou Community Health Center, both in
202	Bamako.
203	
204	The first participant was enrolled in Guinea in January 2024 and in Mali in February 2024. Additional

sites in either country may be opened depending on the enrollment rates and available funding.

#### 206 Amendment

207 After screening the first 33 potential participants with suspected measles, laboratory results confirmed 208 measles was present in only 15 (45.5%), showing that the clinical diagnosis does not always match the 209 validated laboratory assay results. Due to concerns that true measles cases were being missed because 210 the IgM test was possibly conducted too early, prior to development of the IgM response but after the 211 viremic period leading to false negative results [34-37], the protocol was amended. Thus, children highly 212 suspected of measles based on their clinical presentation but who tested negative on both PCR and IgM 213 at day 0 may have an optional visit between days 7-10 to retest for measles IgM [34-37]. Adding a day 214 7-10 re-test allows more time for the IgM response to develop. Optional photography of participants 215 being screened as potential cases was also added to the protocol. Photographs of the rash in confirmed 216 measles cases will be used to train study staff to improve recognition of acute MeV infection in dark 217 skinned children and serve as an educational tool for the medical community. In screened potential 218 cases who test measles negative, these photos will be coupled with the information gained in the 219 exploratory aim of unbiased sequencing of other pathogens to determine the phenotype of other febrile 220 rash illnesses that may otherwise be clinically diagnosed as measles.

## 221 Laboratory and stored specimens

222	The RNA is extracted from the NP/OP swabs collected in viral transport media (VTM) at screening and
223	tested by RT-PCR for MeV. Remaining VTM samples will be stored for sequencing and genotyping of
224	MeV. Samples from children with signs and symptoms consistent with measles but who test negative
225	are stored and can be examined for other viruses using pathogen discovery sequencing methods.
226	Measles IgG and IgM are measured using an enzyme linked immunoassay on plasma samples. The
227	screening tests used in each country (hemoglobin, pregnancy, measles serology, HIV) all underwent
228	verification prior to study start to ensure the reproducibility and accuracy of the results. Plasma
229	collected at baseline (Visit 0), week 13 (Visit 5) and week 52 (Visit 11) will be tested at a commercial
230	laboratory in the United States to measure antibody binding to epitopes of select viruses, bacteria and
231	parasites using validated multiplex serological methods (e.g., Molecular Indexing of Proteins by Self-
232	Assembly [MIPSA] technology with an updated library and additional libraries with endemic bacteria and
233	parasites) [26, 38]. PBMCs are isolated from blood specimens, stored in liquid nitrogen, and will be
234	analyzed for ASC. Plasma obtained following rabies vaccination will be shipped to a commercial
235	laboratory accredited to perform Rapid Fluorescent Foci Inhibition Test (RFFIT) to ensure neutralizing
236	antibody (RVNA) response to the rabies vaccine and to compare cases to controls and those randomized
237	to early vaccination versus late vaccination. Samples not used for analyses will be stored and managed
238	electronically in the local biorepositories under appropriate temperature with constant monitoring.

# 239 Safety reporting and monitoring

240 Safety reporting and monitoring is done according to national regulatory guidelines and International

- 241 Council for Harmonisation (ICH). A clinician with appropriate expertise (Principal Investigator
- 242 [PI]/Designee) will assess adverse event (AE) severity, according to the "Division of AIDS Table for

- 243 Grading the Severity of Adult and Pediatric Adverse Events"
- 244 (https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf) and determine the
- seriousness, relatedness and expectedness of the event. This may be done in coordination with the
- sponsor, NIAID. Per study specific standard operating procedure, only AEs related to study procedures
- will be followed through resolution or until the local investigator judges that the event has stabilized,
- and no additional follow-up is required. Safety events will be tracked and submitted to the local ethics
- 249 committees according to each country's requirements as described in the site-specific appendices. All
- AEs will be recorded on source documents.
- 251
- AEs related to the research procedures and all serious adverse events (SAEs) will be recorded in the

253 research database, except for Grade 1 or 2 AEs that are expected. SAEs and Unanticipated Problems will

be reported to Sanofi Pasteur with coded data according to the terms of a confidential Clinical Trials

255 Agreement.

#### 256 Statistical aspects

257 The overall sample size of the study is 256 participants, 128 enrolled as cases and 128 as controls. The 258 sample size accounts for a 6.5% rate of dropout from the study and participants who drop out will not 259 be replaced. The sample size is calculated to detect a difference in the RVNA geometric mean titer 260 between the measles cases and controlswho were either vaccinated at the early time point or at the late 261 time point). If each vaccination group (early/late) contains 128 participants with 64 cases and 64 262 controls, there will be 90% power to detect a difference of 0.85 between cases and controls under each 263 of the vaccination conditions. There will also be 90% power to detect an interaction between group 264 (measles/controls) and time (early/late) if the effect size is 1.19. The interaction corresponds to showing 265 a different response between cases and controls at early and late rabies vaccine stimulus times. There is

266	90% power to detect standardized mean differences of 1.00 when looking for differences in panels of
267	antibodies between cases and controls in each age group. This calculation controls for multiple
268	comparisons. This effect size was similar to those observed in the paper by Mina et al [ $26$ ].
269	
270	Analysis of the rabies antibody response will be performed using multivariate linear regression on the
271	$\log_{10}$ titer values, including terms for case/control group, early/late vaccine, country and an interaction
272	between group and timing of vaccine. Antibody responses to a panel of antigens will be compared
273	between case/control groups using t-tests on change from baseline. Separate analyses will be
274	performed for 2 age groups (1-5 and 6-15 years). A Bonferroni correction will be used to maintain a 2-
275	sided 0.05 error rate by adjusting for the number of antibodies in the panel. A Poisson analysis will be
276	used to compare the number of encounters with medical providers between groups.
277	
278	Control participants who become infected with measles or participants from either group who become
279	pregnant at any time during the study will be censored at the time of infection or pregnancy. A
280	participant who has a potential rabies exposure and receives rabies PEP during the study before s/he is
281	scheduled (randomized) to receive rabies vaccination as PrEP will be excluded from the primary analysis
282	of the rabies vaccine but included in the immune amnesia analysis. Participants who receive at least one
283	dose of rabies PrEP (as randomized) will be analyzed as planned. A Statistical Analysis Plan (SAP) will be
284	prepared for the study before analyses begin.

# 285 Study conduct, data management, operational logistics and challenges

The study leadership consists of a core team of research physicians, statisticians, laboratory research
 scientists, clinical research pharmacist and operational experts from the Division of Clinical Research
 (DCR) of NIAID and both countries. Both countries have clinical research staff and infrastructure

289 supported by DCR. The study protocol was developed collaboratively. The country teams are responsible 290 for submission for ethical review, continuing review reports, quality management plans, protocol 291 deviations, and SAE reports per country regulations and as requested by NIAID. At all stages, regular 292 teleconferences and visits are held and include study leadership, country scientific/medical laboratory, 293 data management and clinical operations teams, and serve as a forum for information exchange on 294 topics such as recruitment, case adjudication, visit adherence, as well as providing feedback and 295 suggestions on study procedures. A Publication Policy has been developed to guide the drafting and 296 review of all study-related abstracts, presentations, and manuscripts, and a Publication Committee that 297 includes representatives from NIAID and each of the country teams will be formed. For requests for 298 secondary use of biospecimens, the Publication Committee will be approached to approve access to 299 biospecimens. Electronic case report forms (CRFs), core standard operating procedure (SOP) documents 300 and manuals of operation (MOP) were developed along with site-specific documents. 301 The study was designed to use electronic data capture into the Clinical Data Management System 302 (CDMS). Malian staff enter data from study-specific paper source documents. Guinean staff use direct 303 data entry into tablets in an online mode, where the data are saved automatically to the CDMS. If 304 internet connection is temporarily disrupted, the data are captured and uploaded to the CDMS once 305 service is restored. This hybrid approach allows for more flexibility across sites, reduces need for 306 printing CRFs, and requires less transcription of data by the sites. Direct data entry also allows sites to 307 address any queries that arise from programmed data checks at time of entry. The completed data are 308 then reviewed by the central data management team for consistency and accuracy. Randomization is 309 also performed electronically in the CDMS.

310 Specimen kits with standard barcodes were designed for specimen collection. The specimens collected 311 are stored in-country under proper conditions with constant temperature monitoring and documented 312 in an electronic system.

A monitoring plan is used for central monitoring, to facilitate compliance with GCP, guidelines and regulations, identify key activities and specify data to be reviewed for the study. Each plan was reviewed by the study teams in Guinea and Mali and the Measles Study protocol team to ensure adherence to the protocol, laboratory, and GCP requirements. In person and virtual trainings on were conducted with the study staff in each country. Refresher trainings are offered as needed.

318 Each country has encountered challenges with study implementation. The Guinean team is working on 319 enhancing its ability to use electronic systems for study documents and sample management, manage a 320 heavy workload for the available laboratory staff, and ensure participants have a good understanding of 321 study processes. The Malian team is working on increasing the number of screened volunteers by 322 involving more community health centers in referring suspected measles cases to the team. Also, to 323 enhance use by community mobilizers and to sensitize community members about the study, flipbooks, 324 a consenting tool depicting the study procedure in easily understood language with images, have been 325 translated into Bambara, the most spoken language in Mali. Because the sites experience power losses 326 that compromise refrigeration, all study vaccines are stored off site where a continuous power supply is 327 assured and transported to the sites as needed. Finally, due to the waxing and waning measles cases in 328 both countries, enrollment is taking longer than expected.

## 329 Conclusion

330 We have designed and launched an international observational study to investigate immune amnesia

331 following MeV infection in Guinea and Mali, which have recurrent measles outbreaks. Despite

- 332 challenges of collaborative protocol development, operationalization and need for multiple
- 333 authorizations to import rabies and measles vaccines, the study was successfully initiated in 2024. This
- effort will add to the literature on measles immune amnesia and response to an immune stimulant by
- 335 providing data in a population that has not been previously examined and will also provide data on MeV
- 336 genotypes circulating in these regions. It may also bring insights to other viral causes of the
- 337 maculopapular rash illness in children. In addition, the photographs of the rash will add to the current
- 338 literature on measles and other rash illnesses in children with dark skin.
- 339

# 340 Acknowledgements

- 341 We thank PREGUI study team members, Centre National de Formation et de Recherche en Santé Rurale
- 342 de Mafèrinyah, Centres de Santé Amélioré de Mafèrinyah, Hôpital Préfectoral de Forecariah,
- 343 Community leaders in Maferyniah and Forecariah, Guinea; UCRC study team members, Centre de Santé
- 344 Communautaire de Bakorobabougou, Centres de Santé de Reference Commune VI, Direction Générale
- 345 de la Santé et de l'Hygiène Publique, Direction Régionale de la Santé of Bamako and Koulikoro,
- 346 Community partners, Mali; Diane Griffin (deceased) and Jessica Rubens, Johns Hopkins University. We
- 347 are grateful to Sanofi-Pasteur for contributions.

# 348 **References**

- 349 1. Frenkel, L.D., *The global burden of vaccine-preventable infectious diseases in children*
- 350 *less than 5 years of age: Implications for COVID-19 vaccination. How can we do better?*
- 351 Allergy Asthma Proc, 2021. **42**(5): p. 378-385.

- 352 2. Vittrup, D.M., et al., *Measles-mumps-rubella vaccine at 6 months of age, immunology*,
- 353 *and childhood morbidity in a high-income setting: study protocol for a randomized*
- 354 *controlled trial*. Trials, 2020. **21**(1): p. 1015.
- 355 3. WHO. *WHO. Measles fact sheet.* 2023 [cited 2024 February 7]; Available from:
- 356 https://www.who.int/en/news-room/fact-sheets/detail/measles.
- 4. WHO. A 30-fold rise of measles cases in 2023 in the WHO European region warrants
- 358 *urgent action*. 2023; Available from: <u>https://www.who.int/europe/news/item/14-12-2023-</u>
- 359 a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-
- 360 <u>action</u>.
- 361 5. Patel MK, G.J., Alexander JP Jr., et al. *Progress toward regional measles elimination* —
- 362 *Worldwide, 2000–2019.* MMWR Morb Mortal Wkly Rep 2020;69:1700–1705 2020;
- 363 Available from: http://dx.doi.org/10.15585/mmwr.mm6945a6.
- 364 6. WHO. African region reported cases of vaccine-preventable diseases (VPDs). 2023;
- 365 Available from: <u>https://immunizationdata.who.int/global/wiise-detail-page/vaccination-</u>
- 366 <u>schedule-for-country\_name?DISEASECODE=&TARGETPOP\_GENERAL</u>=
- 367 7. Diallo, M., et al., *Comparing vaccination coverage before and during COVID-19*
- 368 pandemic in children under one year in the health district of commune V in Bamako,
- 369 *Mali.* BMC Pediatr, 2023. **23**(1): p. 599.
- 370 8. WHO. *Global health observatory data repository*. 2023; Available from:
- 371 https://apps.who.int/gho/data/node.main.A826.
- 372 9. Griffin, D.E., *Measles vaccine*. Viral Immunol, 2018. **31**(2): p. 86-95.
- 373 10. SeyedAlinaghi, S., et al., Impact of COVID-19 pandemic on routine vaccination coverage
- 374 of children and adolescents: A systematic review. Health Sci Rep, 2022. 5(2): p. e00516.

- 375 11. Shet, A., et al., Impact of the SARS-CoV-2 pandemic on routine immunisation services:
- 376 *evidence of disruption and recovery from 170 countries and territories.* Lancet Glob
- 377 Health, 2022. **10**(2): p. e186-e194.
- 378 12. Truelove, S.A., W.J. Moss, and J. Lessler, *Mitigating measles outbreaks in West Africa*
- 379 *post-Ebola*. Expert Rev Anti Infect Ther, 2015. **13**(11): p. 1299-301.
- 380 13. Grundy, J. and B.A. Biggs, *The impact of conflict on immunisation coverage in 16*381 *countries*. Int J Health Policy Manag, 2019. 8(4): p. 211-221.
- 382 14. Jawad, M., et al., Implications of armed conflict for maternal and child health: A
- 383 regression analysis of data from 181 countries for 2000-2019. PLoS Med, 2021. 18(9): p.
  384 e1003810.
- Behrens, L., J.D. Cherry, and U. Heininger, *The susceptibility to other infectious diseases following Measles during a three year observation period in Switzerland*. Pediatr Infect
- 387 Dis J, 2020. **39**(6): p. 478-482.
- Bühl, D., et al., *Specifically increased rate of infections in children post measles in a high resource setting*. Front Pediatr, 2022. 10: p. 896086.
- 390 17. Gadroen, K., et al., Impact and longevity of measles-associated immune suppression: a
- 391 *matched cohort study using data from the THIN general practice database in the UK.*
- 392 BMJ Open, 2018. **8**(11): p. e021465.
- 18. Le, N.T.H., et al., *Biphasic pattern in the effect of severe measles infection; the difference between additive and multiplicative scale.* BMC Infect Dis, 2021. 21(1): p. 1249.
- 395 19. Sato, R. and M. Haraguchi, *Effect of measles prevalence and vaccination coverage on*
- 396 *other disease burden: evidence of measles immune amnesia in 46 African countries.* Hum
- 397 Vaccin Immunother, 2021. **17**(12): p. 5361-5366.

- 398 20. Aaby, P., et al., *The survival benefit of measles immunization may not be explained*
- 399 *entirely by the prevention of measles disease: a community study from rural Bangladesh.*
- 400 Int J Epidemiol, 2003. **32**(1): p. 106-16.
- 401 21. Aaby, P., et al., Non-specific beneficial effect of measles immunisation: analysis of
- 402 *mortality studies from developing countries.* Bmj, 1995. **311**(7003): p. 481-5.
- 403 22. Higgins, J.P., et al., Association of BCG, DTP, and measles containing vaccines with
- 404 *childhood mortality: systematic review.* BMJ, 2016. **355**: p. i5170.
- 405 23. Mina, M.J., Measles, immune suppression and vaccination: direct and indirect
- 406 *nonspecific vaccine benefits.* J Infect, 2017. **74 Suppl 1**: p. S10-s17.
- 407 24. Sørup, S., et al., *Live vaccine against measles, mumps, and rubella and the risk of*
- 408 *hospital admissions for nontargeted infections.* JAMA, 2014. **311**(8): p. 826-35.
- 409 25. Griffin, D., Measles immunity and immunosuppression. Curr Opin Virol, 2021. 46.
- 410 26. Mina, M.J., et al., Measles virus infection diminishes preexisting antibodies that offer


411 protection from other pathogens. Science, 2019. **366**(6465): p. 599-606.

- 412 27. Petrova, V.N., et al., *Incomplete genetic reconstitution of B cell pools contributes to*
- 413 prolonged immunosuppression after measles. Sci Immunol, 2019. 4(41).
- 414 28. Laksono, B.M., et al., Studies into the mechanism of measles-associated immune
- 415 *suppression during a measles outbreak in the Netherlands*. Nat Commun, 2018. **9**(1): p.
- 416 4944.
- 417 29. Cox, R.M., et al., *Therapeutic mitigation of measles-like immune amnesia and*
- 418 *exacerbated disease after prior respiratory virus infections in ferrets.* Nat Commun,
- 419 2024. **15**(1): p. 1189.

- 420 30. WHO. Control of neglected tropical diseases: Rabies, epidemiology and burden of
- 421 *disease: Global burden of dog-transmitted human rabies.* . [cited 2024 February 7];
- 422 Available from: <u>https://www.who.int/teams/control-of-neglected-tropical-</u>
- 423 <u>diseases/rabies/epidemiology-and-burden</u>...
- 424 31. WHO. WHO expert consultation on rabies: WHO-TRS-1012. 2018 [cited 2024 February
- 425 7]; Available from: <u>https://www.who.int/publications/i/item/WHO-TRS-1012</u>.
- 426 32. CDC. *Rabies Postexposure Prophylaxis (PEP)*. 2022; Available from:
- 427 https://www.cdc.gov/rabies/medical\_care/index.html#:~:text=Postexposure%20prophyla
- 428 <u>xis%20(PEP)%20consists%20of,3%2C%207%2C%20and%2014</u>.
- 429 33. WHO. *Measles*. 2023; Available from: <u>https://www.who.int/news-room/fact-</u>
- 430 <u>sheets/detail/measles</u>.
- 431 34. Woo, G.K., et al., Comparison of laboratory diagnostic methods for measles infection
- 432 *and identification of measles virus genotypes in Hong Kong.* J Med Virol, 2010. **82**(10):
- 433 p. 1773-81.
- 434 35. WHO, Manual for the laboratory-based surveillance of measles, rubella, and
- 435 congenital rubella syndrome, in Chapter 3. Clinical specimens for the laboratory confirmation
- 436 *and molecular epidemiology of*
- 437 *measles, rubella, and CRS.*
- 438 36. CDC Pattern of wild test results among patients with wild measles infection, by day from
- 439 rash onset and type of sampling method used-WHO Measdles and Rubella laboratory
  440 network. 2008.
- WHO Measles and rubella laboratory network: 2007 meeting on use of alternative
  sampling techniques for surveillance. 2008. 225 232.
  - 27

- 443 38. Credle, J.J., et al., Unbiased discovery of autoantibodies associated with severe COVID-
- 444 *19 via genome-scale self-assembled DNA-barcoded protein libraries.* Nat Biomed Eng,
- 445 2022. **6**(8): p. 992-1003.

# Figure 1



collection to the extent possible

